From Yahoo Finance: 2025-06-23 01:35:00

Canaccord Genuity analyst Kyle Mikson raised Illumina, Inc. (ILMN) price target from $87 to $99 on June 11, maintaining a Hold rating. CEO Jacob Thaysen highlighted the potential revenue growth and recovery driven by increased clinical volume and wider adoption of the NovaSeq X sequencing system. Canaccord remains cautious but optimistic about Illumina’s performance.

Illumina, Inc. (ILMN) faces pricing challenges affecting its performance. CEO Thaysen emphasized the importance of clinical volume growth for revenue improvement. The company’s expansion plan relies on the broader adoption of the NovaSeq X platform. Canaccord’s increased price target reflects a neutral stance with cautious optimism for Illumina’s execution.

While Illumina (ILMN) shows investment potential, Canaccord suggests other AI stocks with greater upside and lower risk. The company’s performance is expected to improve in the medium term, but certain AI stocks may offer better opportunities. Canaccord remains neutral on Illumina despite positive indicators for future growth.



Read more at Yahoo Finance: Canaccord Raises Price Target Of Illumina, Inc. (ILMN).